Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04583358
Recruitment Status : Recruiting
First Posted : October 12, 2020
Last Update Posted : November 11, 2021
Sponsor:
Information provided by (Responsible Party):
Applied Molecular Transport

Brief Summary:
Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects with Moderate to Severe Ulcerative Colitis.

Condition or disease Intervention/treatment Phase
Ulcerative Colitis Drug: AMT-101 (oral) Other: Placebo (oral) Phase 2

Detailed Description:
This is a Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study to evaluate the Efficacy and Safety of Oral AMT-101 in Subjects with Moderate to Severe Ulcerative Colitis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 102 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects With Moderate to Severe Ulcerative Colitis (LOMBARD)
Actual Study Start Date : August 26, 2020
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : June 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: AMT-101
AMT-101 Tablet
Drug: AMT-101 (oral)
AMT 101 is orally administered biological therapeutic taken once daily

Placebo Comparator: Placebo
Placebo Tablet
Other: Placebo (oral)
Orally administered placebo comparator taken once daily




Primary Outcome Measures :
  1. Change in Mayo Score [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Endoscopic Remission Rate [ Time Frame: 12 weeks ]
  2. Mucosal Healing Rate [ Time Frame: 12 weeks ]
  3. Histologic Remission Rate [ Time Frame: 12 weeks ]
  4. Clinical Remission Rate [ Time Frame: 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female subjects aged 18 to 75 years, inclusive.
  • Diagnosis of moderate to severe UC.
  • Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening and at the randomization visit.
  • Able to participate fully in all aspects of this clinical trial.
  • Written informed consent must be obtained and documented.

Exclusion Criteria:

  • Known gastrologic, or systemic condition that may compromise severity or diagnosis of disease.
  • History or current evidence of colonic or abdominal abnormalities.
  • Prohibited therapies or procedures before the screening period as specified per protocol.
  • A concurrent clinically significant, serious, unstable, or uncontrolled underlying cardiovascular, pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, might confound the study results, pose additional risk to the subject, or interfere with the subject's ability to participate fully in the study.
  • Pregnant or lactating females.
  • Current or recent history of alcohol dependence, illicit drug use, mental or legal incapacitation, or a history of clinically significant psychiatric disorders that, in the opinion of the investigator, may interfere with the subject's ability to comply with the study procedures.
  • Unable to attend study visits or comply with procedures.
  • Previous exposure to AMT-101 or similar and known hypersensitivity to AMT-101 or its excipients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04583358


Contacts
Layout table for location contacts
Contact: AMT Administrator 650-392-0420 LombardStudy@appliedmt.com

Locations
Show Show 51 study locations
Sponsors and Collaborators
Applied Molecular Transport
Layout table for additonal information
Responsible Party: Applied Molecular Transport
ClinicalTrials.gov Identifier: NCT04583358    
Other Study ID Numbers: AMT-101-202
First Posted: October 12, 2020    Key Record Dates
Last Update Posted: November 11, 2021
Last Verified: November 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Applied Molecular Transport:
Inflammatory Bowel Diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Colitis
Colitis, Ulcerative
Ulcer
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases